Finnish pharmaceutical company Orion Corporation (Orion Pharma) (HEL:ORNBV) said on Thursday that it has initiated the TEADCO Phase 1b/2 basket trial evaluating ODM-212, an oral pan-TEAD inhibitor, in combination with standard-of-care therapies across multiple advanced solid tumours.

The study is designed to assess efficacy, safety, dosing, and tolerability in a multi-centre, open-label setting.

The first cohort evaluates ODM-212 with ipilimumab and nivolumab in first-line treatment of advanced malignant pleural mesothelioma, targeting both anti-tumour activity and resistance prevention. The second cohort studies ODM-212 with sotorasib in KRAS G12C mutated non-small cell lung cancer (NSCLC), including patients with and without prior KRAS inhibitor exposure.

A third cohort assesses ODM-212 combined with chemotherapy (nab-paclitaxel/gemcitabine) in metastatic adenocarcinoma of the pancreas, aiming to enhance treatment efficacy.

The programme positions ODM-212 as a potential therapy to address resistance mechanisms across multiple tumour types.